Pornchai Jonglertham, MD

home / authors / pornchai-jonglertham-md

Articles

Locally Advanced Rectal Cancer, What is the Standard of Care?

Locally Advanced Rectal Cancer, What is the Standard of Care?

Mehmet Sitki Copur, MD, FACP;Whitney Wedel, MD;Pornchai Jonglertham, MD;Thomas Zusag, MD;Adam J. Horn, MD
January 15th 2020

A 39-year-old Hispanic male presented with complaints of mucous stools, loss of appetite, rectal bleeding and a 30-pound weight loss within the past several months.

Site Logo

Hypercalcemia in a Patient with Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia

Mehmet Sitki Copur, MD, FACP;Whitney Wedel, MD;Pornchai Jonglertham, MD;Carlene Springer, APRN;Adam J. Horn, MD
December 16th 2019

Progressive Red-to-Violaceous Papules and Plaques on the Neck and Abdominal Skin of a 70-Year-Old Woman

Progressive Red-to-Violaceous Papules and Plaques on the Neck and Abdominal Skin of a 70-Year-Old Woman

Mehmet Sitki Copur, MD, FACP;Karine Turcotte, MD;Kai Fu, MD, PhD;Pornchai Jonglertham, MD
June 19th 2019

A 70-year-old woman developed red-to-violaceous papules, plaques, and nodule- like skin lesions several months prior to her presentation. The skin lesions mostly involved her lower neck and abdominal area. What is the most likely diagnosis?

Pathologic Hip Fracture in a 49-Year-Old Man With Widespread Metastatic Sclerotic Bone Lesions

Pathologic Hip Fracture in a 49-Year-Old Man With Widespread Metastatic Sclerotic Bone Lesions

Mehmet Sitki Copur, MD;Adam J. Horn, MD;Pornchai Jonglertham, MD
January 17th 2019

In this case, we examine a 49-year-old man with widespread metastatic sclerotic bone lesions. What is your diagnosis?

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.
Published: June 26th 2025 | Updated: July 2nd 2025
Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment